

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3356537

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
NAVIDEA BIOPHARMACEUTICALS, INC.	05/15/2015

RECEIVING PARTY DATA

Name:	CAPITAL ROYALTY PARTNERS II L.P.
Street Address:	1000 MAIN STREET, SUITE 2500
City:	HOUSTON
State/Country:	TEXAS
Postal Code:	77002
Name:	CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.
Street Address:	1000 MAIN STREET, SUITE 2500
City:	HOUSTON
State/Country:	CALIFORNIA
Postal Code:	77002
Name:	PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Street Address:	1000 MAIN STREET, SUITE 2500
City:	HOUSTON
State/Country:	TEXAS
Postal Code:	77002

PROPERTY NUMBERS Total: 14

Property Type	Number
Patent Number:	6409990
Patent Number:	8545808
Application Number:	14039648
Application Number:	14338332
PCT Number:	US1447708
Application Number:	62031348
Application Number:	62106194
Patent Number:	7772256
Patent Number:	8193363
Patent Number:	8653274

PATENT

Property Type	Number
Application Number:	14149563
Patent Number:	8163928
Patent Number:	8957215
Patent Number:	7670591

CORRESPONDENCE DATA

Fax Number: (415)693-2222

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4156932000

Email: crhem@cooley.com

Correspondent Name: COOLEY LLP

Address Line 1: 101 CALIFORNIA STREET, 5TH FLOOR

Address Line 4: SAN FRANCISCO, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	321831-102 NAVIDEA
--------------------------------	--------------------

NAME OF SUBMITTER:	C. RHEM
---------------------------	---------

SIGNATURE:	/CR/
-------------------	------

DATE SIGNED:	05/15/2015
---------------------	------------

Total Attachments: 4

source=CRG - Patent Security Agreement#page1.tif

source=CRG - Patent Security Agreement#page2.tif

source=CRG - Patent Security Agreement#page3.tif

source=CRG - Patent Security Agreement#page4.tif

SHORT-FORM PATENT SECURITY AGREEMENT

WHEREAS, NAVIDEA BIOPHARMACEUTICALS, INC. (the “Grantor”) has applied for letters patent and has been granted letters patents in the United States Patent and Trademark Office, and is the owner of the patent applications and patents listed in the attached Schedule of Patents and Patent Applications associated therewith;

WHEREAS, the Grantor has contemporaneously with the execution of this Short-Form Patent Security Agreement entered into the Security Agreement dated as of May 15, 2015 (as modified from time to time, the “Security Agreement”), in which the Grantor has granted certain interests in favor of CAPITAL ROYALTY PARTNERS II L.P., CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” L.P., and PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P. (together, with their successors and assigns, the “Secured Parties”); and

WHEREAS, pursuant to the Security Agreement, the Grantor has agreed with the Secured Parties to execute this Short-Form Patent Security Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor hereby grants to the Secured Parties, to the extent provided in the Security Agreement (the terms and conditions of which are hereby incorporated herein), a security interest in all of its right, title and interest in, to and under all the patents and patent applications whether now owned or at any time hereafter acquired, of the Grantor issued by, or for which applications have been filed with, the United States Patent and Trademark Office, including the patents and applications on the attached Schedule of Patents and Patent Applications, and all related patents and applications thereto, including all reissuances, continuations, continuations-in-part, revisions, extensions, re-examinations thereof, any patents and patent applications claiming priority to said patents and patent applications or from which said patents and patent applications claim priority, and pending applications associated therewith, as collateral security for the prompt and complete payment and performance when due of all the Secured Obligations (as defined in the Security Agreement). Notwithstanding the foregoing, in the event of any conflict between this Short-Form Patent Security Agreement and the Security Agreement, the Security Agreement shall control.

Date: May 15, 2015

IN WITNESS WHEREOF, the party hereto has caused this Short-Form Patent Security Agreement to be duly executed and delivered as of the day and year first above written.

NAVIDEA BIOPHARMACEUTICALS, INC.

By: 

Name: Brent L. Larson

Title: Exec. Vice President/CFO

[Signature Page to Short-Form Patent Security Agreement]

PATENT
REEL: 035653 FRAME: 0444

SCHEDULE OF
REGISTERED PATENTS

PATENTS

Owner	Patent Description/Title	Jurisdiction	Patent Number (if issued)/Application Number (if applied for only)	Issuance Date (if issued)/Filing Date (if applied for only)
Navidea Biopharmaceuticals, Inc.	"Macromolecular Carrier for Drug and Diagnostic Agent Delivery" (Lymphoseek - Composition)	US	6,409,990	6/25/2002
Navidea Biopharmaceuticals, Inc.	"Compositions for radiolabeling DTPA dextran" (Lymphoseek - Formulation)	US	8,545,808	10/1/2013
Navidea Biopharmaceuticals, Inc.	"Compositions for radiolabeling DTPA dextran" (Lymphoseek - Formulation)	US	14/039,648 (Pending)	9/27/2013
Navidea Biopharmaceuticals, Inc./OSU	"Compositions, Methods and Kits for Diagnosing and Treating CD206 Expressing Cell-Related Disorders" (Lymphoseek – New Field/Composition)	US	14/338,332	7/22/2014
Navidea Biopharmaceuticals, Inc./OSU	"Compositions, Methods and Kits for Diagnosing and Treating CD206 Expressing Cell-Related Disorders" (Lymphoseek – New Field/Composition)	PCT	PCT/US14/47708	7/22/2014
Navidea Biopharmaceuticals, Inc.	"Compositions and Methods for Diagnosing and Treating Macrophage Related Disorders Using Carbohydrate Based Macromolecular Carrier" (Lymphoseek – New Field/Composition)	US	62/031,348	7/31/2014
Navidea Biopharmaceuticals,	"Compounds and Compositions for	US	62/106,194	1/21/2015

Inc./OSU	Targeting Macrophages and Other CD206 High Expressing Cells and Methods of Treating and Diagnosing Using Same" (Lymphoseek – New Field/Composition)			
Navidea Biopharmaceuticals, Inc.	"2-Heteroaryl Substituted Benzothiophenes and Benzofuranes" (NAV4694 – Drug Substance)	US	7,772,256	8/10/2010
Navidea Biopharmaceuticals, Inc.	"Compounds Suitable as Precursors to Compounds that are Useful for Imaging Amyloid Deposits" (NAV4694 – Precursor Substance)	US	8,193,363	6/5/2012
Navidea Biopharmaceuticals, Inc.	"Compounds Suitable as Precursors to Compounds that are Useful for Imaging Amyloid Deposits" (NAV4694 – Precursor Substance)	US	8,653,274	2/18/2014
Navidea Biopharmaceuticals, Inc.	"Compounds Suitable as Precursors to Compounds that are Useful for Imaging Amyloid Deposits" (NAV4694 – Precursor Substance)	US	14/149,563 (pending)	1/7/2014
Navidea Biopharmaceuticals, Inc.	"Heteroaryl Substituted Benzothiazoles" (AZD2184)	US	8,163,928	4/24/2012
Navidea Biopharmaceuticals, Inc.	"Heteroaryl Substituted Benzothiazoles" (AZD2184)	US	8,957,215	2/17/2015
Navidea Biopharmaceuticals, Inc.	"Heteroaryl substituted benzoxazoles" (AZD2995)	US	7,670,591	3/2/2010